CD30, Recombinant, Human (TNFRSF8, Tumor Necrosis Factor Receptor Superfamily Member 8, CD30L Receptor, Ki-1 Antigen, Lymphocyte Activation Antigen CD30, D1S166E)

CD30, also known as Ki-1 antigen and , is a 120kD type I transmembrane glycoprotein belonging to the TNF receptor superfamily. Mature human CD30 consists of a 361aa extracellular domain with six cysteine-rich repeats, a 28aa transmembrane segment, and a 188aa cytoplasmic domain. In contrast, mouse and rat CD30 lack 90aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C-terminal 132aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells. However, it is up-regulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity. CD30 binds to CD30 Ligand/ TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells. CD30 signaling co-stimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response. In the absence of antigenic stimulation, it can still induce T cell expression of IL-13. CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells. In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5. An 85-90kD soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage. Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling. Source: Recombinant corresponding to aa1-369 from human TNFRSF8, expressed in mouse myeloma cell line, NS0. Molecular Weight: ~38.4kD Biological Activity: Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin